HighMark Wealth Management LLC Purchases 13,500 Shares of AtriCure, Inc. (NASDAQ:ATRC)

HighMark Wealth Management LLC raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 19.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,725 shares of the medical device company's stock after acquiring an additional 13,500 shares during the quarter. AtriCure makes up 1.5% of HighMark Wealth Management LLC's portfolio, making the stock its 12th largest holding. HighMark Wealth Management LLC owned 0.17% of AtriCure worth $2,559,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ATRC. Arcadia Investment Management Corp MI purchased a new position in shares of AtriCure during the 3rd quarter worth $28,000. Heck Capital Advisors LLC purchased a new position in shares of AtriCure during the 4th quarter valued at $60,000. Venturi Wealth Management LLC lifted its stake in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after buying an additional 2,100 shares in the last quarter. KBC Group NV lifted its stake in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after buying an additional 932 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of AtriCure during the 4th quarter valued at $89,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

AtriCure Price Performance

ATRC stock traded down $0.77 during mid-day trading on Friday, hitting $38.39. The company had a trading volume of 475,360 shares, compared to its average volume of 601,749. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -40.41 and a beta of 1.46. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a quick ratio of 2.59, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $36.23 and a 200 day moving average price of $31.85.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of AtriCure from $61.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Piper Sandler lifted their target price on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Oppenheimer lifted their target price on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Monday, February 10th. Finally, Stifel Nicolaus lifted their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $51.56.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.